Frontage Holdings Corporation
Frontage Holdings Corporation (FGHQF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
fghqf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Frontage Holdings CorporationYou FGHQF | $304M | N/A | — | — |
 Clinuvel Pharmaceuticals Limited CLVLF | $323M | 15.19x | -67.1% | $0.72 |
 Clinuvel Pharmaceuticals Limited CLVLY | $328M | 14.30x | -69.0% | $0.72 |
 Cellectis S.A. CMVLF | $251M | N/A | — | -$0.70 |
 CytoDyn Inc. CYDY | $404M | 109.11x | +136.2% | $0.00 |
 Hansa Biopharma AB (publ) HNSBF | $246M | N/A | — | -$6.58 |
Industry Average 3 peers with valid PE | — | 46.20x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Frontage Holdings Corporation (FGHQF) measures how much investors pay for each dollar of the company's trailing earnings. FGHQF's current PE ratio of N/A is calculated by dividing its stock price of $0.15 by its TTM earnings per share of —.
Frequently asked questions
FGHQF pe ratio · 6 questionsFGHQF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.15 and TTM EPS of —. Data sourced from Financial Modeling Prep via FGHQF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Frontage Holdings Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09